Furthermore, diagnosing ALL with BCR/ABL1-related genetic abnormalities remains challenging due to genetic heterogeneity and cytogenetic recessive rearrangements, necessitating comprehensive examinations, such as FCM, whole-transcriptome sequencing, fluorescence in situ hybridization, or targeted sequencing methods. This evidence concerns the gene BCR and acute lymphoblastic leukemia.